AAREYDRUGS

Aarey Drugs & Pharmaceuticals Share Price

₹54.59 +0.06 (0.11%)

21 Nov, 2024 14:02

SIP TrendupStart SIP in AAREYDRUGS

Start SIP

Performance

  • Low
  • ₹53
  • High
  • ₹55
  • 52 Week Low
  • ₹37
  • 52 Week High
  • ₹75
  • Open Price₹55
  • Previous Close₹55
  • Volume4,174

Investment Returns

  • Over 1 Month -14.89%
  • Over 3 Month -10.32%
  • Over 6 Month + 7.04%
  • Over 1 Year + 18.67%
SIP Lightning

Smart Investing Starts Here Start SIP with Aarey Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Aarey Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.8
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 155
  • P/B Ratio
  • 1.2
  • Average True Range
  • 3.69
  • EPS
  • 2.47
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.21
  • RSI
  • 31.29
  • MFI
  • 36.89

Aarey Drugs & Pharmaceuticals Financials

Aarey Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹54.59
+ 0.06 (0.11%)
pointer
  • stock-down_img
  • Bullish Moving Average 1
  • stock-up_img
  • Bearish Moving Average 15
  • 20 Day
  • ₹60.39
  • 50 Day
  • ₹61.81
  • 100 Day
  • ₹59.92
  • 200 Day
  • ₹55.76

Resistance and Support

55.3 Pivot Speed
  • R3 59.92
  • R2 58.64
  • R1 56.58
  • S1 53.24
  • S2 51.96
  • S3 49.90

What's your outlook on Aarey Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarey Drugs & Pharms. has an operating revenue of Rs. 518.89 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 1% needs improvement, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 72 which is a FAIR score but needs to improve its earnings, a RS Rating of 45 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarey Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-10-01 Others
2024-08-14 Quarterly Results
2024-05-30 Audited Results
2024-03-27 Others Inter alia, to consider the allotment of Equity Shares and Warrants.

Aarey Drugs & Pharmaceuticals F&O

Aarey Drugs & Pharmaceuticals Shareholding Pattern

45.44%
2.75%
47.57%
4.24%

About Aarey Drugs & Pharmaceuticals

  • NSE Symbol
  • AAREYDRUGS
  • BSE Symbol
  • 524412
  • Chairman & Managing Director
  • Mr. Mihir R Ghatalia
  • ISIN
  • INE198H01019

Similar Stocks to Aarey Drugs & Pharmaceuticals

Aarey Drugs & Pharmaceuticals FAQs

Aarey Drugs & Pharmaceuticals share price is ₹54 As on 21 November, 2024 | 13:48

The Market Cap of Aarey Drugs & Pharmaceuticals is ₹154.8 Cr As on 21 November, 2024 | 13:48

The P/E ratio of Aarey Drugs & Pharmaceuticals is 25.8 As on 21 November, 2024 | 13:48

The PB ratio of Aarey Drugs & Pharmaceuticals is 1.2 As on 21 November, 2024 | 13:48

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23